Lipid Changes During Endocrine Therapy in Breast Cancer Patients: The Results of a 5-Year Real-World Retrospective Analysis

The aim of this study was to investigate the status of serum lipids during endocrine therapy. We retrospectively analysed lipid profiles during the 5-year treatment of 1487 consecutive postoperative BC patients. Lipid parameters included triglycerides (TG), total cholesterol (TC), low-density lipopr...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2022-01, Vol.11, p.670897-670897
Main Authors: He, Tao, Li, Xu, Li, Jiayuan, Wang, Zhu, Fan, Yuan, Li, Xiusong, Fu, Zhoukai, Wu, Yunhao, Lv, Qing, Luo, Ting, Zhong, Xiaorong, Chen, Jie
Format: Article
Language:English
Subjects:
anastrozole
breast cancer
endocrine therapy
letrozol
lipids
Oncology
tamoxifen
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to investigate the status of serum lipids during endocrine therapy. We retrospectively analysed lipid profiles during the 5-year treatment of 1487 consecutive postoperative BC patients. Lipid parameters included triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL-C) and high-density lipoprotein (HDL-C). Those biomarkers were measured at baseline and 1, 2, 3, 4 and 5 years following the initiation of endocrine therapy. For premenopausal BC patients, LDL levels rapidly decreased at 1 year in the tamoxifen (TAM) group compared with baseline levels (
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.670897